youcef rustum (16 Ergebnisse)

Zustand: New. In.

Zustand: New. In.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Zustand: New. Editor(s): Rustum, Youcef M. Series: Advances in Experimental Medicine and Biology. Num Pages: 319 pages, biography. BIC Classification: MJCL; PST; PSV. Category: (P) Professional & Vocational. Dimension: 254 x 178 x 17. Weight in Grams: 640. . 2012. 1993rd Edition. paperback. . . . . Books ship from the US and Ireland.

Zustand: New. In.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The therapeutic efficacy of FUra has been attributed to its incorporation into cellular RNA and, to its inhibition of thymidylate synthase, leading to potent inhibition of DNA synthesis and DNA damage. Studies of cell lines in vitro and model systems in vivo have demonstrated that although mechanisms of sensitivity and resistance to FUra are multifactorial, in the presence of citrovorum factor (LV, CF, 5-formyltetrahydrofolate) the site of action of FUr a becomes predominantly the pronounced and prolonged inhibition of thymidylate synthase. This action is the result of stabilization of the covalent ternary complex between FdUMP, an active metabolite of FUr a, 5,IO-methylenetetrahydrofolates, and thymidylate synthase. This effect of LV is thus an example of the concept of metabolic modulation. CF is commercially available as a racemic mixture of diastereoisomers (6R and 6S). The 6R isomer is considered to be biologically inactive; the 6S isomer is the biologically active form that is metabolized intracellularly to' form the various folate cofactor pools including 5,IO-methylenetetrahydrofolates. Although the extent of metabolism of folates in normal and tumor tissues has not been clearly delineated, it has been determined that the formation of folypolyglutamates is primarily a function of schedule of CF administration, while the retention of significant concentrations of reduced folate is a function of the dose and also the schedule of LV. Thus, it appears that for optimal modulation of FUra activity several factors must be considered simultaneously.

Zustand: New. pp. 340 Illus.

Zustand: New. In.

Zustand: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher.

Gebunden. Zustand: New. KlappentextProceedings of an international symposium held in Buffalo, N.Y., September 1992. With the major diseases of focus being advanced and adjuvant colorectal cancer, head and neck cancer, and breast cancers, the volume is divided i.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Fluoropyrimidine Metabolism and Mechanism of Action.- 5-Fluoro-2 -Deoxyuridine: Role of Schedule in its Therapeutic Efficacy.- Comparison of Continuous Infusions and Bolus Injections of 5- Fluorouracil with or without Leucovorin: Implications for Inhibition of Thymidylate Synthase.- Critical Questions for the Future Direction of FU/LV.- Cellular Interactions Between the Natural and Unnatural Isomers of 5-Formyltetrahydrofolate.- Leucovorin as a Prodrug.- Clinical Use of Leucovorin: Intracellular Metabolism.- Some Considerations Concerning the Dose and Schedule of 5FU and Leucovorin: Toxicities of Two Dose Schedules from the Intergroup Colon Adjuvant Trial (INT-0089).- Effects of 5-Fluorouracil on mRNA.- Genetic Variation in Thymidylate Synthase Confers Resistance to 5-Fluorodeoxyuridine.- Experience with 5FU + L-Leucovorin.- 5-Fluorouracil Combined with the Pure [6S]-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients with Advanced Colorectal Carcinoma: A Phase I-II Study of Two Consecutive Regimens.- 5-Fluorouracil Modulation in Colorectal Carcinoma: Experience of German Investigators.- An Overview of Adjuvant Treatment of Colon Cancer.- Dose-Dependent Inhibition of Aspartate Carbamoyltransferase in Peripheral Blood Mononuclear Cells in Patients Receiving N-Phosphonacetyl)-L-Aspartate.- Alternative Approaches to Modulation of Fluoropyrimidines.- Increasing the Efficacy of 5-Fluorouracil with Interferons: Preclinical, Clinical, and Pharmacokinetic Studies.- Enchanced Cytotoxicity of 5-Fluorouracil Combined with [6RS]-Leucovorin and Recombinant Human Interferon- 2a in Colon Carcinoma Cells.- Regulation of Thymidylate Synthase in Human Colon Cancer Cells Treated with 5-Fluorouracil and Interferon-Gamma.- Biochemical Modulation of 5-Fluorouracil by PALA: Mechanism of Action.- Implications of Chronobiology for 5-Fluorouracil (5-FU) Efficacy.- Update on Metabolic Modulation as a Therapeutic Approach for Adult Carcinomas.- Fluorouracil and Leucovorin in Advanced Breast Cancer.- Fluorouracil Modulation in Head and Neck Cancer.- Biomodulation in Head and Neck Carcinomas: Therapeutic Approaches in Europe.- Rationale for the Combination Therapy of 5FU and CDDP.- Biochemical Modulation of Fluoropyrimidines: The 'Giscad' Studies.- New Drugs.- Clinical Experience with UFT in Japan.- Clinical Studies of the Modulation of Ftorafur.- The Role of the Reduced-Folate Carrier and Metabolism to Intracellular Polyglutamates for the Activity of ICI D1694.- The History of the Development and Clinical Use of CB 3717 and ICI D1694.- New Sites of Intervention in the Development of New Drugs in Solid Tumors.- P53: A Determinant of the Cell Cycle Response to DNA Damage.- Therapeutic Implications of Molecular Genetics.- Concluding Remarks.- Summary.- Abbreviations.- Author Index.

Zustand: New. pp. 332 9 Illus.

Hardcover. Zustand: Brand New. 336 pages. 10.25x7.00x1.00 inches. In Stock.

Zustand: New. In.

Zustand: New. Editor(s): Rustum, Youcef M. Series: Cancer Drug Discovery and Development. Num Pages: 326 pages, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 254 x 178 x 18. Weight in Grams: 647. . 2010. 1st ed. Softcover of orig. ed. 2003. Paperback. . . . . Books ship from the US and Ireland.

Zustand: New. Reviews the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. This book considers combination agents such as UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and various thymidylate synthase inhibitors. Editor(s): Rustum, Youcef M. Series: Cancer Drug Discovery and Development. Num Pages: 326 pages, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 254 x 178 x 20. Weight in Grams: 807. . 2002. 2003rd Edition. hardcover. . . . . Books ship from the US and Ireland.